This study investigates the effects of adding an investigational medication to standard treatment for pancreatic cancer.
The study evaluates how the investigational medication affects overall survival, progression-free survival, and quality of life. It focuses on the safety and effectiveness of the treatment.
- Who can participate: Adults aged 18 and older with metastatic pancreatic cancer, who have not received prior treatment for this condition, may participate.
- Study details: Participants will receive standard treatment with either an investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine.